Group: Team

Cody Kirk

Cody comes to Aceragen as lead financial planner having managed the PricewaterhouseCoopers (PwC) private practice for the Southeast market and assisted clients with various technical accounting matters. His portfolio includes industries such as biotech, health care, manufacturing, and retail and consumer, which ranged from $100M to $1B+ in revenues. He brings in credible skill in

Christina Lockhart

Christina focuses on management for rare disease and novel therapy studies. She has developed study management tools, processes and procedures that facilitate operations from study conception to study close-out. Prior to joining Aceragen, she spearheaded a COVID-19 treatment trial with the focus on rapid study take-off. With over 18 years’ working in pharma, biotech, CROs

Travis Autrey

Travis is the Senior Director of Finance at Aceragen, one of our team’s money management leaders. Prior to Aceragen, he worked for Ology Bioservices, Inc. as they built their contract development and manufacturing organization operations. There, he managed more than $1 billion dollars’ worth of government and commercial CDMO contracts, assisted in raising over $100

Bryan Hoang

Bryan serves as our Senior Manager of Project Management, a leader in therapy development processes. He has numerous patents and publications on targeted therapeutics, radioimmunotherapy, small molecule compounds and sustained drug delivery systems. Bryan has more than 10 years of experience in developing transformative medicines for the treatment of chronic indications including oncology, CNS diseases

Carl Kraus

Carl guides Aceragen researchers and doctors in their work to deliver safe, effective treatments. He is an Infectious Disease physician with more than 20 years’ experience in drug development, ranging from discovery and first-in-man studies through late-phase/risk-management program implementation. Carl has been the Principal Investigator for multiple NIAID, NCI and DoD-funded research programs and an

Denise Watts

As Manager of Project Administration, Denise keeps Aceragen’s clinical operations expenditures in order. She has a wide breadth of knowledge in business, administration and pharmaceutical sciences, having worked in drug development for more than 15 years across clinical research organizations and biotechnology companies. Denise has broad experience in supporting clinical trial programs as well as

Noah Wolfson

The Senior Director of Project Management, Noah comes to Aceragen as a key lead in our research and development activities. He has served in a diverse set of roles in biotech, consulting, venture and academia. Prior to joining the Aceragen team, Noah worked at Molekule Consulting where he advised the management of top pharmaceutical companies

Greg Spalla

Greg leads supply chain operations at Aceragen. His primary duties include managing the production and transportation of key materials, anticipating and reducing future supply “risks”, and working with internal stakeholders and key CMO partners. He has nearly 30 years of experience managing supply chain organizations for global, commercial pharmaceutical and emerging biotech companies. Over the

Liang Ding

Liang joins Aceragen with chemistry, manufacturing and controls analytical and bioanalytical experiences in drug development for rare diseases. Previously, Liang worked at CRISPR Therapeutics, Homology Medicines and Tessera Therapeutics. He and his team developed analytical methods to characterize and quality control modalities, Cas9/gRNA, mRNA, lipid nanoparticles, virus and proteins. He worked on LC/MS-MS assays, cell-based

Gwen Thomas

Gwen serves as Associate Director of Business and Project Management. Whether in front of a customer or behind the scenes — locally or internationally — her organizational skills, keen attention to detail and coordinated execution achieve results with distinction. Prior to her career in the biotech industry, Gwen worked in IT and non-profit development. Her